Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maureen Trudeau

Showing results (41-50 of 106) with videos related to

Pageof 11
Sort By:
The Lancet. Oncology|November 1, 2005
Selection of adjuvant chemotherapy for treatment of node-positive breast cancerMaureen Trudeau, Flay Charbonneau, Karen Gelmon, et al.
Breast Cancer Research and Treatment|February 4, 2009
Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancersSharon Nofech-Mozes, Maureen Trudeau, Harriet K Kahn, et al.
Cancer|July 6, 2017
Establishing achievable benchmarks for quality improvement in systemic therapy for early-stage breast cancerMelanie Powis, Rinku Sutradhar, Alejandro Gonzalez, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 30, 2010
Key components of intravenous chemotherapy labeling: a systematic review and practice guidelineMaureen Trudeau, Esther Green, Roxanne Cosby, et al.
The American Journal of Managed Care|February 6, 2013
Closing the personalized medicine information gap: HER2 test documentation practiceIlia L Ferrusi, Craig C Earle, Maureen Trudeau, et al.
Plos One|February 4, 2022
Developing the Breast Utility Instrument, a preference-based instrument to measure health-related quality of life in women with breast cancer: Confirmatory factor analysis of the EORTC QLQ-C30 and BR45 to establish dimensionsTeresa C O Tsui, Maureen Trudeau, Nicholas Mitsakakis, et al.
JAMA Oncology|February 24, 2022
Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast CancerWei Fang Dai, Jaclyn M Beca, Chenthila Nagamuthu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancerJonas Bergh, Per-Ebbe Jönsson, Elisabet Kerstin Lidbrink, et al.
The Oncologist|January 27, 2018
Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, CanadaSofia Torres, Maureen Trudeau, Sonal Gandhi, et al.
The Lancet. Oncology|April 28, 2009
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II studyBella Kaufman, Maureen Trudeau, Ahmad Awada, et al.
Pageof 11

Showing results (41-50 of 106) with videos related to

Sort By:
Pageof 11
The Lancet. Oncology|November 1, 2005
Selection of adjuvant chemotherapy for treatment of node-positive breast cancerMaureen Trudeau, Flay Charbonneau, Karen Gelmon, et al.
Breast Cancer Research and Treatment|February 4, 2009
Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancersSharon Nofech-Mozes, Maureen Trudeau, Harriet K Kahn, et al.
Cancer|July 6, 2017
Establishing achievable benchmarks for quality improvement in systemic therapy for early-stage breast cancerMelanie Powis, Rinku Sutradhar, Alejandro Gonzalez, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 30, 2010
Key components of intravenous chemotherapy labeling: a systematic review and practice guidelineMaureen Trudeau, Esther Green, Roxanne Cosby, et al.
The American Journal of Managed Care|February 6, 2013
Closing the personalized medicine information gap: HER2 test documentation practiceIlia L Ferrusi, Craig C Earle, Maureen Trudeau, et al.
Plos One|February 4, 2022
Developing the Breast Utility Instrument, a preference-based instrument to measure health-related quality of life in women with breast cancer: Confirmatory factor analysis of the EORTC QLQ-C30 and BR45 to establish dimensionsTeresa C O Tsui, Maureen Trudeau, Nicholas Mitsakakis, et al.
JAMA Oncology|February 24, 2022
Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast CancerWei Fang Dai, Jaclyn M Beca, Chenthila Nagamuthu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancerJonas Bergh, Per-Ebbe Jönsson, Elisabet Kerstin Lidbrink, et al.
The Oncologist|January 27, 2018
Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, CanadaSofia Torres, Maureen Trudeau, Sonal Gandhi, et al.
The Lancet. Oncology|April 28, 2009
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II studyBella Kaufman, Maureen Trudeau, Ahmad Awada, et al.
Pageof 11